Clinical Trials Browser

Phase 2 × Recruiting × incomplete Freund's adjuvant × Clear all

NCT06202066 2026-03-11

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Phase 2 Recruiting

Adenoma, Islet Cell